New medical insurance price of trametinib, a special drug for lung cancer in 2024

The original drug Trametinib (Trametinib) has been launched in China and is included in the scope of medical insurance. Reimbursement is limited to patients who meet the indications, including melanoma, non-small cell lung cancer, etc. Eligible patients can enjoy the national medical insurance reimbursement policy when purchasing trametinib at local hospitals and other places. Patients who do not meet the conditions can only purchase it at their own expense.

Trametinib is aMEK1/2 inhibitor, which mainly affects the MAPK pathway and inhibits cell proliferation through its effect on MEK protein. Trametinib is indicated for the treatment of unresectable or metastatic melanoma with a BRAF (murine sarcoma oncogenic homolog B1 gene) V600E or V600K mutation, non-small cell lung cancer that is not curable with surgery or has spread to other parts of the body (metastasis), or to prevent melanoma from coming back after surgery, for which there are no other treatments for metastatic non-small cell lung cancer or advanced or metastatic anaplastic thyroid cancer.

Common specifications of the domestically marketed trametinib original drugThe price of 2mg*30 tablets is more than RMB 10,000. The reimbursement ratio is different in different regions. The price after reimbursement may be different, but it will definitely be cheaper than the original price. The price of the original trametinib drug sold overseas is more than RMB 7,000 (the price may fluctuate due to the exchange rate) for 2mg*30 tablets. There are also generic trametinib drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 2mg*30 tablets produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.